FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293514394> ?p ?o ?g. }

• W4293514394 endingPage "108272" @default.
• W4293514394 startingPage "108272" @default.
• W4293514394 abstract "For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron supplementation has been the mainstay of treatment for anemia in chronic kidney disease (CKD). Although ESAs are well-established and highly efficacious treatment, clinical trials demonstrated that the use of ESAs with a high hemoglobin (Hb) target was associated with increased risk of cardiovascular events. This safety concern raised considerable interest in developing an alternative therapeutic strategy. Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are such novel agents to treat anemia in CKD. They stimulate endogenous erythropoietin production via HIF activation and thereby induce erythropoiesis. At least 6 small-molecule HIF-PHIs have been developed to date. The phase 3 clinical trials demonstrated that their effects were noninferior to ESAs. HIF-PHIs may have several advantages over the conventional treatment, such as oral route of administration and their ability to raise Hb levels in patients with chronic inflammation. Although many of the phase 3 clinical trials demonstrated that HIF-PHIs were noninferior to placebo or ESAs with respect to cardiovascular safety, one of the compounds failed to meet the prespecified noninferiority criterion in non-dialysis-dependent CKD patients, and some studies of another HIF-PHI indicated potential risks for thromboembolic events. While the regulatory agencies of some countries including Japan and the European Union concluded that roxadustat, one of the HIF-PHIs, had a favorable benefit-risk profile, the U.S. Food and Drug Administration decided not to approve the drug because of safety reasons. In order to establish the optimal anemia management in CKD, further studies are needed to evaluate important aspects of HIF-PHIs, such as long-term safety, appropriate Hb target, and the types of patients who would gain benefits from these new drugs." @default.
• W4293514394 created "2022-08-30" @default.
• W4293514394 creator A5007057754 @default.
• W4293514394 creator A5036113498 @default.
• W4293514394 creator A5046647870 @default.
• W4293514394 date "2022-11-01" @default.
• W4293514394 modified "2023-10-17" @default.
• W4293514394 title "Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors" @default.
• W4293514394 cites W1965845267 @default.
• W4293514394 cites W1967145414 @default.
• W4293514394 cites W1984393349 @default.
• W4293514394 cites W1990220461 @default.
• W4293514394 cites W1991047577 @default.
• W4293514394 cites W1998943227 @default.
• W4293514394 cites W2002549547 @default.
• W4293514394 cites W2005973637 @default.
• W4293514394 cites W2017575850 @default.
• W4293514394 cites W2030992731 @default.
• W4293514394 cites W2040029744 @default.
• W4293514394 cites W2040031153 @default.
• W4293514394 cites W2042222205 @default.
• W4293514394 cites W2044257922 @default.
• W4293514394 cites W2048923069 @default.
• W4293514394 cites W2052201224 @default.
• W4293514394 cites W2058062704 @default.
• W4293514394 cites W2061342616 @default.
• W4293514394 cites W2090627731 @default.
• W4293514394 cites W2095160894 @default.
• W4293514394 cites W2100628130 @default.
• W4293514394 cites W2101084498 @default.
• W4293514394 cites W2101901896 @default.
• W4293514394 cites W2124116160 @default.
• W4293514394 cites W2130304025 @default.
• W4293514394 cites W2133231668 @default.
• W4293514394 cites W2134487085 @default.
• W4293514394 cites W2136548506 @default.
• W4293514394 cites W2138126378 @default.
• W4293514394 cites W2144625075 @default.
• W4293514394 cites W2156426667 @default.
• W4293514394 cites W2170744592 @default.
• W4293514394 cites W2171230374 @default.
• W4293514394 cites W2178101235 @default.
• W4293514394 cites W2206481924 @default.
• W4293514394 cites W2339445416 @default.
• W4293514394 cites W2607303896 @default.
• W4293514394 cites W2704386052 @default.
• W4293514394 cites W2801814883 @default.
• W4293514394 cites W2889535805 @default.
• W4293514394 cites W2903992936 @default.
• W4293514394 cites W2914891827 @default.
• W4293514394 cites W2918824768 @default.
• W4293514394 cites W2945654236 @default.
• W4293514394 cites W2961921650 @default.
• W4293514394 cites W2963534431 @default.
• W4293514394 cites W2964045421 @default.
• W4293514394 cites W2977026040 @default.
• W4293514394 cites W2981787444 @default.
• W4293514394 cites W2985232847 @default.
• W4293514394 cites W2991201427 @default.
• W4293514394 cites W2995413545 @default.
• W4293514394 cites W3003395581 @default.
• W4293514394 cites W3007850211 @default.
• W4293514394 cites W3012148201 @default.
• W4293514394 cites W3029930991 @default.
• W4293514394 cites W3045732747 @default.
• W4293514394 cites W3108166106 @default.
• W4293514394 cites W3112489277 @default.
• W4293514394 cites W3127251493 @default.
• W4293514394 cites W3128080784 @default.
• W4293514394 cites W3130258858 @default.
• W4293514394 cites W3132161708 @default.
• W4293514394 cites W3135755919 @default.
• W4293514394 cites W3147209760 @default.
• W4293514394 cites W3155331209 @default.
• W4293514394 cites W3155430778 @default.
• W4293514394 cites W3157159493 @default.
• W4293514394 cites W3159725307 @default.
• W4293514394 cites W3160338797 @default.
• W4293514394 cites W3162927584 @default.
• W4293514394 cites W3164802324 @default.
• W4293514394 cites W3183678333 @default.
• W4293514394 cites W3188004162 @default.
• W4293514394 cites W3199229819 @default.
• W4293514394 cites W3199302640 @default.
• W4293514394 cites W3199318191 @default.
• W4293514394 cites W3200128890 @default.
• W4293514394 cites W3206319755 @default.
• W4293514394 cites W3208950730 @default.
• W4293514394 cites W4200289499 @default.
• W4293514394 cites W4224228384 @default.
• W4293514394 cites W4224298532 @default.
• W4293514394 cites W4225632556 @default.
• W4293514394 cites W4225709603 @default.
• W4293514394 cites W4293879745 @default.
• W4293514394 cites W3149132779 @default.
• W4293514394 doi "https://doi.org/10.1016/j.pharmthera.2022.108272" @default.
• W4293514394 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36031160" @default.
• W4293514394 hasPublicationYear "2022" @default.

• next